Anemia: Clinical Trials

41 trials for Anemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

41 terminated. 41 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 441Terminated 41

Follow Anemia: new trials by email Literature Review of Anemia trials Research Report on Anemia

Trials (filtered) newest first · largest first

All 41 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
IRONICA: IRON Repletion In Heart Failure - A Comparison of Oral and IV Approaches
Ferric Carboxymaltose, Ferrous Sulfate - Heart Failure, Heart Failure With Reduced Ejection Fraction (HFrEF)
Phase 4TerminatedSyed Hamza Mufarrih422025-04-022026-07-20
Effects of IV Iron Replacement on Exercise Capacity in Individuals With Heart Failure
IV Iron Infusion Group - Heart Failure, Iron-deficiency
Phase 4TerminatedRadha Gopalan62024-01-242026-07-29
Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder
Ferrous sulfate - Sleep Disorder, Restless Legs Syndrome
Phase 4TerminatedMayo Clinic62020-11-162024-05-22
Daily Versus Alternate Day Iron Supplementation for the Treatment of Iron Deficiency Anemia in Pregnancy
Ferrous sulfate - Pregnancy Related, Iron Deficiency Anemia of Pregnancy
Phase 4TerminatedThe University of Texas Medical Branch, Galveston142020-10-272024-06-24
Desmopressin for Bedwetting in Children With SCD
Desmopressin - Nocturnal Enuresis, Anemia, Sickle Cell
Phase 4TerminatedMontefiore Medical Center82020-07-072024-05-07
Study to Assess Feasibility and Safety of Iron Repletion With Feraheme in Iron Deficient Patients With Durable Ventricular Assist Device Support
Ferumoxytol injection - Anemia
Phase 4TerminatedNYU Langone Health12020-01-152023-07-18
ORal IrON Supplementation With Ferric Maltol in Patients With Heart Failure Carrying Left Ventricular Assist Devices
Ferric maltol 30 mg (Feraccru®) - Heart Failure, Left Sided, Anemia, Iron Deficiency
Phase 4TerminatedHannover Medical School112019-03-182020-04-21
Assessing a Risk Model for G6PD Deficiency
primaquine, chloroquine + primaquine - Malaria, Vivax, G6PD Deficiency
Phase 4TerminatedPATH542018-05-072021-11-12
Frequent, Low-Dose Erythropoietin A Mechanistic Approach to Mitigate Adverse Cardiovascular Effects of Erythropoietin
Low dose erythropoietin, High dose erythropoietin - Anemia, CKD
Phase 4TerminatedVA Office of Research and Development52017-11-022020-08-13
A Double Blind Randomised Placebo-controlled Trial to Assess the Role of Iron Repletion in Glucose Homeostasis.
Ferric Carboxymaltose, 0.9% sodium chloride solution - Iron-deficiency, Iron Toxicity
Phase 4TerminatedProf Gérard WAEBER322017-06-212020-03-26
Long-term Safety and Efficacy of Ferriprox® in Iron Overloaded Patients With Sickle Cell Disease or Other Anemias
Deferiprone - Iron Overload, Sickle Cell Disease
Phase 4TerminatedApoPharma1342015-05-212024-01-10
The Use of Iron Therapy for Patients With Anemia After Caesarean Section
Ferinject, Ferrous fumarate, Placebo for ferrous fumarate - Postoperative Anaemia
Phase 4TerminatedMaastricht University Medical Center272015-03-022022-08-22
Paricalcitol Improves Anemia of Inflammation
Paricalcitol, Epoetin beta, Placebo - Anemia
Phase 4TerminatedHospital Son Espases192014-12-012024-12-09
Pre-operative Treatment With Erythropoietin and Iron Supplement in Cardiac Surgery
Erythropoietin subcutaneously and Iron intravenously - Heart; Dysfunction Postoperative, Cardiac Surgery, Anemia, Iron-Deficiency
Phase 4TerminatedCatharina Ziekenhuis Eindhoven72014-08-012017-04-05
Safety and Efficacy of Exjade in the Treatment of Transfusion-dependent Iron Overload in Aplastic Anemia Patients
ICL670, Chelation, No chelation - Aplastic Anemia
Phase 4TerminatedNovartis Pharmaceuticals152014-06-232019-08-16
Efficacy and Safety of Ferriprox® in Patients With Sickle Cell Disease or Other Anemias
Deferiprone, Deferoxamine - Iron Overload, Sickle Cell Disease
Phase 4TerminatedApoPharma2302014-04-172021-08-10
The Effect of Epogen and Venofer Dosing Management on Hemoglobin Stability
Individualized Anemia Mangement Protocol - Anemia, End Stage Renal Disease
Phase 4TerminatedMichael Germain482013-07-012014-03-26
Correcting Anemia and Native Vitamin D Supplementation in Kidney Transplant Recipients
High Hb target, cholecalciferol - Kidney Transplantation, Anemia
Phase 4TerminatedCANDLE-KIT Trial Study Group1612013-04-012019-02-04
Evaluation of the Conversion From Peginesatide to Epoetin Alfa in Patients Receiving Hemodialysis
Peginesatide, Epoetin alfa - Anemia
Phase 4TerminatedAmgen412012-10-012014-04-21
Intravenous Ferric Carboxymaltose (Ferinject) in Patients Undergoing Orthopaedic Surgery
Ferinject 50 mg/ml, NaCl 0.9% - Anemia, Orthopedic Surgery
Phase 4TerminatedUniversity Hospital Muenster32011-06-012013-08-09

Showing 20 of 41. Sign in to see all of them.

Narrower conditions

Anemia, Iron-Deficiency (9)  ·  Anemia, Sickle Cell (6)  ·  Kidney Failure, Chronic (6)  ·  Renal Insufficiency, Chronic (6)  ·  Heart Failure (3)  ·  Iron Deficiencies (3)  ·  Kidney Diseases (3)  ·  Iron Overload (2)  ·  Neoplasms (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Anemia, Aplastic (1)  ·  Atherosclerosis (1)  ·  Bone Diseases, Metabolic (1)  ·  Cardiovascular Diseases (1)

Broader conditions

Hemic and Lymphatic Diseases (41)  ·  Hematologic Diseases (40)  ·  Metabolic Diseases (14)  ·  Nutritional and Metabolic Diseases (14)  ·  Iron Metabolism Disorders (12)  ·  Urogenital Diseases (12)  ·  Female Urogenital Diseases (11)  ·  Female Urogenital Diseases and Pregnancy Complications (11)  ·  Male Urogenital Diseases (11)  ·  Pathological Conditions, Signs and Symptoms (11)  ·  Urologic Diseases (11)  ·  Anemia, Hypochromic (9)  ·  Chronic Disease (9)  ·  Disease Attributes (9)

Interventions

Epoetin Alfa (8)  ·  ferric carboxymaltose (8)  ·  ferrous sulfate (5)  ·  epoetin beta (4)  ·  Erythropoietin (3)  ·  Iron (3)  ·  Deferiprone (2)  ·  Ibuprofen (2)  ·  Sodium Chloride (2)  ·  continuous erythropoietin receptor activator (2)  ·  ferryl iron (2)  ·  Chelating Agents (1)  ·  Chloroquine (1)  ·  Cholecalciferol (1)  ·  Contraceptives, Oral (1)

Sponsors

Hoffmann-La Roche (5)  ·  Ortho Biotech Products, L.P. (3)  ·  ApoPharma (2)  ·  Amgen (1)  ·  CANDLE-KIT Trial Study Group (1)  ·  Catharina Ziekenhuis Eindhoven (1)  ·  Children's Hospital Medical Center, Cincinnati (1)  ·  Children's Hospital of Philadelphia (1)  ·  Hannover Medical School (1)  ·  Hospital Son Espases (1)  ·  Indiana University (1)  ·  Janssen Cilag S.A.S. (1)  ·  Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1)  ·  London North West Healthcare NHS Trust (1)  ·  Maastricht University Medical Center (1)

Countries

United States (17)  ·  United Kingdom (4)  ·  Germany (3)  ·  Belgium (2)  ·  Canada (2)  ·  Egypt (2)  ·  France (2)  ·  Netherlands (2)  ·  Saudi Arabia (2)  ·  Spain (2)  ·  Switzerland (2)  ·  Venezuela (2)  ·  Australia (1)  ·  Brazil (1)  ·  Greece (1)

Top investigators

Janet Kwiatkowski, MD (2)  ·  Andrew Talal, MD (1)  ·  Anna Maria van Eijk, MD PhD (1)  ·  Arjunan Ganesh, MD (1)  ·  Caroline Dore, BSc (1)  ·  Charles T. Quinn, MD (1)  ·  Gary Hoel, RPh, PhD (1)  ·  Gavin Cho, MD (1)  ·  Hugo K Van Aken, PhD, MD (1)  ·  Jan Schmitto, Prof. MD (1)

Results publications

PMID 36791280, PMID 17108343, PMID 21876446, PMID 27288381, PMID 30051186, PMID 30853478, PMID 32331365, PMID 34847228, PMID 35363499, PMID 35706490, PMID 35956390, PMID 36018224, PMID 37807937, PMID 38828109, PMID 39185895, PMID 39443013

NIH funding

2016 (1), I01CX001449 (1), U01DK071633 (1), U54HL070588 (1)